Your browser doesn't support javascript.
loading
Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma.
Barta, Stefan K; Zain, Jasmine; MacFarlane, Alexander W; Smith, Sonali M; Ruan, Jia; Fung, Henry C; Tan, Carlyn R; Yang, Yibin; Alpaugh, R Katherine; Dulaimi, Essel; Ross, Eric A; Campbell, Kerry S; Khan, Nadia; Siddharta, Rawat; Fowler, Nathan H; Fisher, Richard I; Oki, Yasuhiro.
Afiliación
  • Barta SK; Department of Hematology and Oncology, Fox Chase Cancer Center, Philadelphia, PA; Department of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA. Electronic address: stefan.barta@uphs.upenn.edu.
  • Zain J; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Cancer Center, Duarte, CA.
  • MacFarlane AW; Department of Blood Cell Development and Function, Fox Chase Cancer Center, Philadelphia, PA.
  • Smith SM; Department of Hematology/Oncology, University of Chicago, Chicago, IL.
  • Ruan J; Department of Hematology and Oncology, Weill Cornell Medicine, New York, NY.
  • Fung HC; Department of Hematology and Oncology, Fox Chase Cancer Center, Philadelphia, PA.
  • Tan CR; Department of Hematology and Oncology, Fox Chase Cancer Center, Philadelphia, PA.
  • Yang Y; Department of Blood Cell Development and Function, Fox Chase Cancer Center, Philadelphia, PA.
  • Alpaugh RK; Protocol Support Laboratory, Fox Chase Cancer Center, Philadelphia, PA.
  • Dulaimi E; Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA.
  • Ross EA; Department of Biostatistics, Fox Chase Cancer Center, Philadelphia, PA.
  • Campbell KS; Department of Blood Cell Development and Function, Fox Chase Cancer Center, Philadelphia, PA.
  • Khan N; Department of Hematology and Oncology, Fox Chase Cancer Center, Philadelphia, PA.
  • Siddharta R; Office of Clinical Research, Fox Chase Cancer Center, Philadelphia, PA.
  • Fowler NH; Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX.
  • Fisher RI; Department of Hematology and Oncology, Fox Chase Cancer Center, Philadelphia, PA.
  • Oki Y; Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX.
Clin Lymphoma Myeloma Leuk ; 19(6): 356-364.e3, 2019 06.
Article en En | MEDLINE | ID: mdl-31029646
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfoma de Células T Periférico / Anticuerpos Monoclonales Humanizados / Receptor de Muerte Celular Programada 1 / Antineoplásicos Inmunológicos Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Lymphoma Myeloma Leuk Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfoma de Células T Periférico / Anticuerpos Monoclonales Humanizados / Receptor de Muerte Celular Programada 1 / Antineoplásicos Inmunológicos Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Lymphoma Myeloma Leuk Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article